Study of Epratuzumab in Systemic Lupus Erythematosus
NCT00383513
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
29
Enrollment
INDUSTRY
Sponsor class
Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL:
Epratuzumab
Sponsor
UCB Pharma